Article title: Anti-IL 23 biologics for the treatment of plaque psoriasis
Authors: Vu, A., Ulschmid, C., & Gordon, K. B.
Journal: EXPERT OPINION ON BIOLOGICAL THERAPY
DOI: https://doi.org/10.1080/14712598.2022.2132143
When this article was first published, and contained incorrect information regarding the approval for use of risankizumab and guselkumab in psoriatic arthritis (PsA). The following changes have been made to correct this:
Table 1. Current Biologic Therapies for Moderate-to Severe-Psoriasis
Table 2. Current IL-23 Inhibitor Therapies for Moderate-to-Severe Psoriasis
In , PsA Approval has been changed from No to Yes for both guselkumab and risankizumab.
In , PsA Approval has been changed from No to Yes for both guselkumab and risankizumab. An additional footnote (g) has been added that states “Risankizumab and guselkumab have been approved for the treatment of psoriatic arthritis in adult patients by both the FDA and EMA as of 2022.”